These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10392258)

  • 1. The relevance of experimental models in the pathogenetic investigation of primary IgA nephropathy.
    Montinaro V; Gesualdo L; Schena FP
    Ann Med Interne (Paris); 1999 Feb; 150(2):99-107. PubMed ID: 10392258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary IgA nephropathy: the relevance of experimental models in the understanding of human disease.
    Montinaro V; Gesualdo L; Schena FP
    Nephron; 1992; 62(4):373-81. PubMed ID: 1300432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgA nephropathy: lessons from an animal model, the ddY mouse.
    Tomino Y
    J Nephrol; 2008; 21(4):463-7. PubMed ID: 18651534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights in the pathogenesis of IgA nephropathy.
    Monteiro RC
    Nefrologia; 2005; 25 Suppl 2():82-6. PubMed ID: 16050408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate immunity and IgA nephropathy.
    Coppo R; Amore A; Peruzzi L; Vergano L; Camilla R
    J Nephrol; 2010; 23(6):626-32. PubMed ID: 20383870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgA nephropathy in alcohol abuse. An animal model.
    Smith SM; Yu GS; Tsukamoto H
    Lab Invest; 1990 Feb; 62(2):179-84. PubMed ID: 2304330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interferon-gamma and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients.
    Masutani K; Miyake K; Nakashima H; Hirano T; Kubo M; Hirakawa M; Tsuruya K; Fukuda K; Kanai H; Otsuka T; Hirakata H; Iida M
    Am J Kidney Dis; 2003 Feb; 41(2):371-9. PubMed ID: 12552499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression.
    Izzi C; Ravani P; Torres D; Prati E; Viola BF; Guerini S; Foramitti M; Frascà G; Amoroso A; Ghiggeri GM; Schena FP; Scolari F
    Am J Kidney Dis; 2006 May; 47(5):761-9. PubMed ID: 16632014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation.
    Tang Z; Ji SM; Chen DR; Wen JQ; Chen JS; Liu ZH; Li LS
    Ren Fail; 2008; 30(6):611-6. PubMed ID: 18661411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA-nephropathy: triumph of immunology or misconception?
    Beukhof JR; Fleuren GJ; Hoedemaeker PJ; Donker AJ; The TH; Ockhuizen T; Van der Hem GK
    Neth J Med; 1984; 27(10):393-404. PubMed ID: 6392909
    [No Abstract]   [Full Text] [Related]  

  • 11. New insights into the pathogenesis of IgA nephropathy. Pathogenesis of IgA nephropathy.
    Smith AC; Feehally J
    Springer Semin Immunopathol; 2003 May; 24(4):477-93. PubMed ID: 12778340
    [No Abstract]   [Full Text] [Related]  

  • 12. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications.
    Takemura T; Okada M; Yagi K; Kuwajima H; Yanagida H
    Pediatr Nephrol; 2002 Oct; 17(10):863-6. PubMed ID: 12376818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy.
    Espinosa M; Ortega R; Gómez-Carrasco JM; López-Rubio F; López-Andreu M; López-Oliva MO; Aljama P
    Nephrol Dial Transplant; 2009 Mar; 24(3):886-91. PubMed ID: 18842673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of secretory IgA and complement in IgA nephropathy.
    Oortwijn BD; Eijgenraam JW; Rastaldi MP; Roos A; Daha MR; van Kooten C
    Semin Nephrol; 2008 Jan; 28(1):58-65. PubMed ID: 18222347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options.
    Tumlin JA; Madaio MP; Hennigar R
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):1054-61. PubMed ID: 17702711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA nephropathy. From molecules to men.
    Tomino Y
    Contrib Nephrol; 1999; 126():III-IX, 1-115. PubMed ID: 10489630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA nephropathy: an update on pathogenesis and classification.
    Mubarak M
    J Coll Physicians Surg Pak; 2011 Apr; 21(4):230-3. PubMed ID: 21453621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes.
    Haas M; Rahman MH; Cohn RA; Fathallah-Shaykh S; Ansari A; Bartosh SM
    Nephrol Dial Transplant; 2008 Aug; 23(8):2537-45. PubMed ID: 18263928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coxsackie B viruses and the kidney--a neglected topic.
    Pasch A; Frey FJ
    Nephrol Dial Transplant; 2006 May; 21(5):1184-7. PubMed ID: 16490748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
    Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
    J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.